Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Aeon Biopharma Inc (AEON)

Aeon Biopharma Inc (AEON)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 12,903
  • Shares Outstanding, K 11,838
  • Annual Sales, $ 0 K
  • Annual Income, $ 42,010 K
  • EBIT $ -10 M
  • EBITDA $ -10 M
  • 60-Month Beta 0.72
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.17
  • Number of Estimates 1
  • High Estimate -0.17
  • Low Estimate -0.17
  • Prior Year 3.75
  • Growth Rate Est. (year over year) -104.53%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.9112 +19.62%
on 02/12/26
1.4500 -24.83%
on 02/23/26
-0.0200 (-1.80%)
since 02/04/26
3-Month
0.6507 +67.51%
on 12/05/25
1.4500 -24.83%
on 02/23/26
+0.3415 (+45.62%)
since 12/04/25
52-Week
0.3750 +190.67%
on 04/11/25
1.4500 -24.83%
on 02/23/26
+0.6100 (+127.08%)
since 03/04/25

Most Recent Stories

More News
AEON Biopharma Reports BPD Type 2a Meeting with FDA and Shareholder Approval of the November Transactions

-  AEON confirmed that earlier today it held its BPD Type 2a Meeting with the FDA, in line with prior guidance, and is now awaiting official meeting minutes - - Separately, AEON shareholders today...

AEON : 1.0900 (unch)
AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711

IRVINE, Calif., Dec. 19, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company seeking accelerated and full-label U.S. market...

AEON : 1.0900 (unch)
AEON Biopharma Announces Execution of Exchange Agreement with Daewoong

- AEON and Daewoong Pharmaceutical have executed definitive documentation to exchange $15 million of notes plus accrued interest into new equity, $1.5 million of new notes due 2030, and a cash-exercise...

AEON : 1.0900 (unch)
AEON Biopharma Announces First Closing of PIPE Investment and Provides Update on FDA Type 2a Meeting Scheduling

-  First closing of PIPE resulted in ~$1.79M in proceeds - - FDA BPD Type 2a meeting now scheduled for January 21, 2026 - IRVINE, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc....

AEON : 1.0900 (unch)
AEON Biopharma Reports Third Quarter 2025 Results, Including Positive ABP-450 Biosimilarity Data and Strategic Positioning for Continued Growth

– FDA Type 2a meeting scheduled for November 19, 2025, to review AEON’s analytical development plan and initial data – – Positive biosimilarity data for ABP-450 confirming identical amino-acid...

AEON : 1.0900 (unch)
AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711

AEON : 1.0900 (unch)
AEON Biopharma to Present at the Aegis Capital Corp. Virtual Conference 2025

AEON : 1.0900 (unch)
AEON Biopharma Reports First Quarter 2025 Financial Results and Provides Corporate Update

AEON : 1.0900 (unch)
AEON Biopharma Announces NYSE American Acceptance of Plan to Regain Listing Compliance

AEON : 1.0900 (unch)
AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711

AEON : 1.0900 (unch)

Business Summary

AEON Biopharma Inc. is a clinical-stage biopharmaceutical company. It focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions. AEON Biopharma Inc., formerly known as Priveterra Acquisition Corp., is based in IRVINE, Calif.

See More

Key Turning Points

3rd Resistance Point 1.3333
2nd Resistance Point 1.2667
1st Resistance Point 1.1783
Last Price 1.0900
1st Support Level 1.0233
2nd Support Level 0.9567
3rd Support Level 0.8683

See More

52-Week High 1.4500
Last Price 1.0900
Fibonacci 61.8% 1.0394
Fibonacci 50% 0.9125
Fibonacci 38.2% 0.7857
52-Week Low 0.3750

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar